Tenon Medical (NASDAQ:TNON) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS

Tenon Medical (NASDAQ:TNON) released its quarterly earnings results on Tuesday. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.01), Zacks reports. The firm had revenue of $1.38 million for the quarter, compared to analyst estimates of $1.30 million. Tenon Medical had a negative net margin of 270.09% and a negative return on equity of 560.04%.

Here are the key takeaways from Tenon Medical’s conference call:

• Tenon reported Q1 revenue of $1.4 million, nearly doubling year over year, with gross margin expanding to 68.5% from 44.5% last year. Management said these were the best first-quarter revenue and gross profit results in company history.
• Growth was driven by higher Catamaran procedure volumes and the first full quarter of meaningful SImmetry+ contribution after the SiVantage acquisition. The company said physician training and adoption remained strong, with 21 physicians trained during the quarter.
• The company closed a $4.3 million senior convertible note financing in March, which it said extends runway and supports ongoing investment in commercialization, product launches, and clinical programs. Cash and equivalents ended the quarter at $4.6 million, up from $3.8 million at year-end 2025.
• Management highlighted an expanding intellectual property portfolio, now at 29 U.S. patents and 9 international patents granted with 31 applications pending. It also pointed to multiple notices of allowance expected to convert into additional patents later in 2026.
• Tenon outlined several future growth catalysts, including a full SImmetry+ launch, additional platform enhancements in the second half of 2026, and a new approach to the sacro-pelvic anatomy targeted for alpha in Q4 2026. Management expects these launches, along with continued physician training, to support growth into 2027 and beyond.

Tenon Medical Price Performance

TNON traded up $0.01 on Thursday, reaching $0.73. 70,908 shares of the company traded hands, compared to its average volume of 717,759. The company has a market cap of $8.28 million, a price-to-earnings ratio of -0.57 and a beta of 1.28. The stock’s 50 day moving average price is $0.78 and its 200-day moving average price is $0.93. Tenon Medical has a 52-week low of $0.64 and a 52-week high of $2.48.

Analyst Ratings Changes

Several equities analysts have weighed in on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Tenon Medical in a research report on Monday, April 20th. Alliance Global Partners reaffirmed a “buy” rating on shares of Tenon Medical in a research report on Wednesday. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Tenon Medical currently has a consensus rating of “Hold”.

Institutional Investors Weigh In On Tenon Medical

Institutional investors have recently modified their holdings of the stock. DRW Securities LLC acquired a new position in shares of Tenon Medical in the fourth quarter worth $98,000. Geode Capital Management LLC increased its position in Tenon Medical by 34.6% in the 4th quarter. Geode Capital Management LLC now owns 66,640 shares of the company’s stock worth $63,000 after purchasing an additional 17,137 shares during the last quarter. Finally, Jane Street Group LLC purchased a new stake in shares of Tenon Medical during the 1st quarter worth about $29,000. Institutional investors and hedge funds own 22.74% of the company’s stock.

Tenon Medical Company Profile

Tenon Medical, Inc is a development-stage medical device company focused on the research, development and commercialization of next-generation surgical biologic adhesives and sealants. The company’s proprietary platform is designed to create tissue-compatible adhesives that can serve as alternatives or complements to traditional sutures and staples, with the goal of improving surgical efficiency, reducing postoperative complications and enhancing patient outcomes.

Tenon Medical’s product pipeline centers on protein-based polymer formulations that cross-link in situ to form a flexible, yet durable, bond with native tissue.